Release date: 30 January 2020
Promoter – Financial Intermediary
ITM ISOTOPEN TECHNOLOGIEN MUENCHEN AGLocation
Description
The project concerns RDI investments of a proprietary portfolio of nuclear medicine solutions for diagnosis and treatment of cancer, addressing a range of indications such as neuroendocrine tumours, bone metastases or prostate cancers. This portfolio includes new radionuclides and radiopharmaceuticals in various stages of clinical development, covering discovery, pre-clinical and clinical (Phase I-III) and technical validation phases.
Objectives
The project falls within the scope of the Horizon 2020 programme Societal Challenges (Health, Demographic Change and Wellbeing).
Sector(s)
- Services - Professional, scientific and technical activities
Proposed EIB finance (Approximate amount)
EUR 40 million
Total cost (Approximate amount)
EUR 92 million
Environmental aspects
The project mainly concerns investments in R&D (process development, clinical studies, regulatory development/production capacity, etc.) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an EIA under the Directive 2014/52/EU amending the EIA Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Procurement
The promoter is a private company not operating in the utilities sector and is thus not covered by EU Directives on procurement.
Status
Signed - 20/12/2019